header logo image


Page 25«..1020..24252627..3040..»

Archive for the ‘Regenerative Medicine’ Category

Stem Cell Therapy Market to 2027 – Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography – P&T Community

Saturday, April 18th, 2020

NEW YORK, April 15, 2020 /PRNewswire/ -- The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans.This raises the importance of creating public awareness about stem cell research and its clinical potential.

The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user.Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.

The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous.

The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.Based on application type, the stem cell therapy market has been segmented into musculoskeletal, dermatology, cardiology, drug discovery and development, and other applications.

The musculoskeletal segment held the largest share of the stem cell therapy market in 2019, whereas the drug discovery and development segment is expected to report the highest CAGR during 20202027. Based on end user, the market has been segmented into academic and research institutes, and hospitals and specialty clinics. The academic & research institutes held the largest share of the market in 2019, and it is also expected to report the highest CAGR during the forecast period.Several essential secondary sources referred to for preparing this report are the FDA, World Health Organization (WHO), Organisation for Economic Co-operation and Development, National Institutes of Health, Spanish Agency for Medicines (AEMPS), Japanese Society for Regenerative Medicine, and Indian Council of Medical Research, among others.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/stem-cell-therapy-market-to-2027---global-analysis-and-forecasts-by-type-treatment-application-end-user-and-geography-301041155.html

SOURCE Reportlinker

Continued here:
Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography - P&T Community

Read More...

Preclinical Study Showing Beneficial Effects of Cymerus MSCs in Acute Respiratory Distress Syndrome Accepted for Publication in Leading Peer-Reviewed…

Saturday, April 18th, 2020

MELBOURNE, Australia, April 17, 2020 (GLOBE NEWSWIRE) --Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that a scientific paper describing the use of Cymerus mesenchymal stem cells (MSCs) in a model of Acute Respiratory Distress Syndrome (ARDS) has been accepted for publication in the American Journal of Respiratory and Critical Care Medicine (AJRCCM).1The AJRCCM, commonly known as The Blue Journal, is widely regarded as the foremost peer-reviewed journal in the field of respiratory and critical care medicine.

Background

The study was conducted in 14 sheep with severe ARDS supported by extracorporeal membrane oxygenation (ECMO), which were given an endobronchial infusion of either Cymerus MSCs (n=7) or placebo (n=7). Animals were monitored and supported for 24 hours, at which time the study concluded.

ARDS is an inflammatory process leading to build-up of fluid in the lungs and respiratory failure. It can occur due to a range of insults, including infection, trauma and inhalation of noxious substances. It has received significant global attention in recent times, as it is one of the most serious complications experienced by patients suffering from COVID-19. ARDS accounts for approximately 10% of all ICU admissions and almost 25% of patients requiring mechanical ventilation, and results in hospital mortality ofup to 46%.2 In addition, survivors of ARDS are often left with severe long-term illness and disability.3

ECMO is a last-line intervention used in patients whose lungs are unable to provide an adequate amount of oxygen to the blood, despite the use of ventilators and other interventions. ECMO circulates blood through an artificial lung, oxygenating the blood before returning it to the patients circulation. ECMO can help support the vital organs in patients with severe ARDS, but it is not in itself a treatment for ARDS and the mortality among patients supported by it remains high.

This study was conducted independently of Cynata by a group of leading academics known as the Combining Extracorporeal Life Support and Cell Therapy in Critical Illness (CELTIC)Investigators, led by Professor John Fraser of the Critical Care Research Group, The Prince Charles Hospital, Brisbane. The study was funded by the Queensland Government, the National Health and Medical Research Council (NHMRC), the Intensive Care Society UK, and the Prince Charles Hospital Foundation.

Key Results

Cymerus MSC treatment was shown to exert a number of important beneficial effects in this study:

There were no statistically significant differences in oxygenation index between groups. The authors of the paper suggested that this may have been due to the severity of the lung injury induced; the fact that the observation period may have been too short to observe all beneficial effects of the treatment; and practical challenges performing these assessments during ECMO.

The authors also observed that a different dose regimen and/or route of administration could lead to further improved outcomes.

The study also found that MSCs adhere to the membranes in the ECMO device, resulting in a significant increase in pressure, and there was a higher incidence of thrombosis in the lungs observed post-mortem. While this did not lead to failure of the ECMO device or other observed adverse events, the study team considered that it could potentially do so, and therefore concluded that they cannot currently recommend the use of MSCs in combination with ECMO. It is important to note that this finding is relevant to MSCs in general (regardless of source), as it is related to the propensity of MSCs to adhere to plastic, but it does not have implications for the treatment of patients with ARDS who are NOT receiving ECMO.

Dr Kilian Kelly, Cynatas Chief Operating Officer, commented:

We are very encouraged by the beneficial effects of Cymerus MSCs on a number of important, clinically-relevant endpoints in this model of ARDS. These results provide valuable guidance on the potential clinical utility of Cymerus MSCs in the treatment of ARDS. It is also very useful to learn more about the practical mechanical challenges associated with administering MSCs at the same time as ECMO, but it is important to note that most patients with ARDS do not receive ECMO. Furthermore, in humans with ARDS who are not receiving ECMO, we expect to be able to administer repeated intravenous infusions of MSCs, which may have advantages compared to the approach that was taken in this preclinical study. We are currently in discussions with leading key opinion leaders about a possible clinical trial in human patients with ARDS, including those who have developed ARDS as a result of the devastating COVID19 pandemic.

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynatas lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, sepsis, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.

______________________

1 Millar JE, Bartnikowski N, Passmore MR, et al. Combined Mesenchymal Stromal Cell Therapy and ECMO in ARDS: A Controlled Experimental Study in Sheep. Am J Crit Care Med, 2020.2 Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. Jama. 2016;315(8):788.3 Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14):1293-304.

View original post here:
Preclinical Study Showing Beneficial Effects of Cymerus MSCs in Acute Respiratory Distress Syndrome Accepted for Publication in Leading Peer-Reviewed...

Read More...

Visiongain Report: The Gene Therapy Market is Projected to Grow at a CAGR of 32% in the First Half of the Forecast Period – P&T Community

Saturday, April 18th, 2020

Gene Therapy R&D and Revenue Forecasts 2020-2030

Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Cancer, Rare Diseases, Cardiovascular Disorders, Ophthalmologic Conditions, Infectious Disease, Neurological Disorders, Diabetes Mellitus

LONDON, April 17, 2020 /PRNewswire/ -- The gene therapy market is projected to grow at a CAGR of 32% in the first half of the forecast period. In 2019, the cancer treatment submarket accounted for 55.8% of the gene therapy drug market. Visiongain estimated that gene therapy for rare diseases will be the driver for market growth in the first half of the forecast period.

How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 215-page report you will receive 157 charts all unavailable elsewhere.

The 215-page Visiongain report provides clear detailed insight into the gene therapy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/gene-therapy-rd-and-revenue-forecasts-2020-2030/#download_sampe_div

Report Scope

Gene Therapy market forecasts from2020-2030

This report assesses the approved gene therapy products in the market and gives revenue to 2030

Provides qualitative analysis and forecast of the submarket by indication for the period 2020-2030: Cancer Cardiovascular disorders Rare diseases Ophthalmological diseases Infectious Diseases Neurological Disorders Diabetes Mellitus Other therapeutic uses

Profiles leading companies that will be important in the development of the gene therapy market. For each company, developments and outlooks are discussed and companies covered in this chapter include: UniQure Biogen Bluebird Bio Spark Therapeutics Applied Genetics Technologies Corporation Oxford Biomedica GenSight Biologics & Other Companies

Assesses the outlook for the leading gene treatment R&D pipeline for 2019 and discusses technological progress and potential. Profiles appear for gene therapy drug candidates, with revenue forecasts for four leading agents: Collategene (AMG0001, AnGes MG/Vical) BC-819 (BioCancell) BC-821 BioCancell SPK-CHM Spark Therapeutics SPK-FIX Spark Therapeutics/Pfizer SPK-TPP1- Spark Therapeutics Lenti-D (Bluebird Bio) LentiGlobin (Bluebird Bio) VM202-DPN ViroMed

Provides qualitative analysis of trends that will affect the gene therapies market, from the perspective of pharmaceutical companies, during the period 2020 to 2030. SWOT analysis is provided and an overview of regulation of the gene therapy market by leading region given.

Our study discusses factors that influence the market including these: Translation of research into marketable products modifying human DNA gene transfer for therapeutic use, altering the nuclear genome Genomic editing technology and other supporting components Collaborations to develop and launch gene-based products acquisitions and licensing deals Supporting technologies for human genetic modification, gene replacement and targeted drug delivery Gene therapies for ophthalmologic diseases next-generation medicines Regulations in the United States, the European Union and Japan overcoming technological and medical challenges to pass clinical trials.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/gene-therapy-rd-and-revenue-forecasts-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

4DMT (4D Molecular Therapeutics)AbeonaAGTC (Applied Genetics Technologies Corporation)AMT (Amsterdam Molecular Therapeutics) AnGes MGAsklepios BioPharmaAstraZenecaAudentes TherapeuticsAvalanche BiotechBayer HealthcareBeijing Northland Biotech CoBenda PharmaceuticalBenitec BiopharmaBioCancellBiogenBiogen IdecBluebird BioBMS (Bristol-Myers Squibb)Broad Institute/Whitehead InstituteCelgeneCell Therapy CatapultCellectisChiesi Farmaceutici Clearside BiomedicalConvergence PharmaceuticalsDaiichi Sankyo Dimension TherapeuticsEditas MedicineFondazione TelethonFrancis Crick Institute Genable Technologies LtdGenethonGenSight BiologicsGenVecGoogleGSK (GlaxoSmithKline)Henry Ford Health SystemHSCI (Human Stem Cells Institute)HSR-TIGET (San Raffaele Telethon Institute for Gene Therapy), ImaginAbImmune Design Corp InoCardInovioIntellia TherapeuticsInvetechKite PharmaKolon GroupKolon Life ScienceLysogeneMitsubishi Tanabe Pharma Corporation NeuralgeneNightstaRxNorthwestern Memorial HospitalNovartisOXB (Oxford Biomedica)PfizerPNP TherapeuticsPrecision Genome Engineering Inc aka PregenenProNaiProtek GroupRaffaele HospitalREGENX BiosciencesRenova TherapeuticsRocheRoszdravnadzorSangamo BiosciencesSanofiSarepta TherapeuticsShanghai Sunway BiotechShenzhen SiBiono GeneTechSotex Pharm Firm Spark TherapeuticsSynerGene TherapeuticsTakara BioTAP BiosystemsThermo Fisher ScientificTissueGeneToolGenUC BerkeleyUC San Francisco uniQureUS Business Innovation Network Vertex PharmaceuticalsVical IncorporatedViroMedVM BiopharmaVoyage Therapeutics

List of Organisation Mentioned ASCO (American Society of Clinical Oncology)ASI (Agency for Strategic Initiatives) CAT (Committee for Advanced Therapies) CBER (Center for Biologics Evaluation and Research)CHMP (Committee for Medicinal Products for Human Use)CHOP (The Children's Hospital of Philadelphia)DCGI (Drugs Controller General of India)DHHS (Department of Health and Human Services)EMA (European Medicines Agency)FDA (US Food and Drug Administration)INSERM (Institut National de la Sant et de la Recherche Mdicale) IRB (Institutional Review Boards) MFDS (Korean Ministry of Food and Drug Safety) MHLW (Ministry of Health, Labour, and Welfare)MHRA (Medicines and Healthcare Products Regulatory Agency)Ministry of Health Commission NHS (National Health Service)NICE (the National Institute for Health and Care Excellence)NIH (National Institutes of Health) OHRP (Office for Human Research Protections)PMDA (Pharmaceuticals and Medical Devices Agency) RCGM (Review Committee of Genetic Manipulation) Russian Ministry of Healthcare and Social DevelopmentSFDA (State Food and Drug Administration of China) SMC (Scottish Medicines Consortium) The Fund for Promotion of Small Innovative Enterprises in Science and TechnologyThe IGI (Innovative Genomics Initiative)The Innovative Genomics Initiative The Walter and Eliza Hall Institute The Wellcome Trust Sanger Institute WFH (World Federation of Hemophilia)WHO (World Health Organization)

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Translational Regenerative Medicine Market Forecast 2020-2030

Global Precision Medicine Market Forecast 2019-2029

Global Stem Cell Technologies and Applications Market 2019-2029

Generic Drugs Market Forecast 2019-2029

Biobanking Market Forecasts 2019-2029

Global Liquid Biopsy Market Forecast to 2029

Next-Generation Biologics Market Forecast to 2029

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

See the original post here:
Visiongain Report: The Gene Therapy Market is Projected to Grow at a CAGR of 32% in the First Half of the Forecast Period - P&T Community

Read More...

New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion’s SEP-363856 for the Treatment of Schizophrenia – Business Wire

Saturday, April 18th, 2020

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that results of a four-week pivotal study (SEP361-201) evaluating the safety and efficacy of SEP-363856 in patients with schizophrenia were published online in the New England Journal of Medicine (NEJM).

In this study, once-daily, flexible-dose (50-75 mg) treatment with SEP-363856 demonstrated a statistically significant and clinically meaningful improvement in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo after four weeks of treatment (-17.2 vs. -9.7, respectively; p=0.001). Patients treated with SEP-363856 also showed improvement in the overall severity of illness as assessed by the Clinical Global Impression Scale - Severity (CGI-S) (p<0.001). In addition, improvement was observed in all major PANSS (positive, negative and general psychopathology) subscales (p<0.02). SEP-363856 was well tolerated throughout the study and the overall discontinuation rate was comparable for SEP-363856 and placebo.1

These data represent an exciting step forward in schizophrenia research. The steps that led to identifying this new mechanism of action, targeting TAAR1, were very novel and they reflected a courageous and innovative approach by Sunovion to identifying new ways to treat schizophrenia, said John Krystal, M.D., Chair of Psychiatry and Co-Director, Yale Center for Clinical Investigation at Yale School of Medicine and co-author of the NEJM publication. For the last 60 years, antipsychotics that bind to dopamine receptors have been the standard of care, despite their side effect profile. It is my hope that these results for SEP-363856 support a new schizophrenia treatment for people who have been diagnosed with this serious mental health condition. SEP-363856 could have a big impact on people with schizophrenia, their families, and on the public health burden posed by schizophrenia.

SEP-363856 is a novel trace amine-associated receptor 1 (TAAR1) agonist with serotonin 1A (5-HT1A) agonist activity that is being evaluated in patients with schizophrenia. SEP-363856 does not bind to dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors, which are thought to mediate the effects of currently available atypical antipsychotic medicines. SEP-363856 is being studied in the DIAMOND (Developing Innovative Approaches for Mental Disorders) Phase 3 global development program for schizophrenia with additional indications under consideration. The U.S. FDA granted Breakthrough Therapy Designation for SEP-363856 for the treatment of schizophrenia in May 2019.

Publication of these findings in the New England Journal of Medicine demonstrates the potential of SEP-363856 to be the first TAAR1 agonist for the treatment of schizophrenia, said Kenneth Koblan, PhD, Chief Scientific Officer of Sunovion. This innovative approach to the treatment of schizophrenia may provide a completely new option for the 23 million people worldwide who live with this serious mental health condition. Sunovion is committed to developing new treatment options for these patients and continuing to study SEP-363856 to further evaluate its clinical benefit in schizophrenia and other neuropsychiatric conditions.

As noted in the NEJM publication, in the six-month, open-label extension study, SEP-363856 demonstrated continued improvement across efficacy measures, including the PANSS total score, the CGI-S score, and the Brief Negative Symptom Scale (BNSS) total score and appeared to be safe and well-tolerated.

About SEP-363856SEP-363856 is a TAAR1 agonist with 5-HT1A agonist activity that is under investigation for the treatment of schizophrenia and other psychiatric conditions. Sunovion discovered SEP-363856 in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms. SEP-363856 is being studied in a global Phase 3 development program for schizophrenia (DIAMOND) with additional indications under consideration. The U.S. FDA granted Breakthrough Therapy Designation for SEP-363856 for schizophrenia in May 2019.

About SchizophreniaSchizophrenia is a chronic, serious and often severely disabling brain disorder that affects more than 23 million people worldwide2 and approximately one in 100 adults (about 2.4 million people) in the United States.3 It is characterized by positive symptoms, such as hallucinations, delusions and disorganized thinking as well as negative symptoms, such as lack of emotion, social withdrawal, lack of spontaneity and cognitive impairment that includes problems with memory, attention and the ability to plan, organize and make decisions.2

About Sunovion Pharmaceuticals Inc. (Sunovion)Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovions vision is to lead the way to a healthier world. The companys spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.

Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the companys websites: http://www.sunovion.com, http://www.sunovion.eu and http://www.sunovion.ca. Connect with Sunovion on Twitter, LinkedIn, Facebook and YouTube.

About Sumitomo Dainippon Pharma Co., Ltd.Sumitomo Dainippon Pharma is among the top-10 listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China, and the European Union. Sumitomo Dainippon Pharma aims to create innovative pharmaceutical products in the Psychiatry & Neurology area, the Oncology area and Regenerative medicine/Cell therapy field, which have been designated as the focus therapeutic areas. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at https://www.ds-pharma.com.

SUNOVION is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. 2020 Sunovion Pharmaceuticals Inc. All rights reserved.

For a copy of this release, visit Sunovions website at http://www.sunovion.com

References

1 Koblan, K., Kent, J., Hopkins, S., Krystal, J., Cheng, H., Goldman, R., Loebel, A., A non-D2 Binding Drug for the Treatment of Schizophrenia. New England Journal of Medicine. April 16, 2020, Vol. 382, Issue 16, p. 1497-1506. Available online: https://www.nejm.org/doi/full/10.1056/NEJMoa1911772. Accessed April 2020.2 World Health Organization. Mental Disorders. [Internet]. Available from: https://www.who.int/news-room/fact-sheets/detail/mental-disorders. Accessed September 2018.3 National Institute of Mental Health. Schizophrenia. [Internet]. Available from: https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml. Accessed September 2018.

More:
New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion's SEP-363856 for the Treatment of Schizophrenia - Business Wire

Read More...

Predictive Submits Emergency Use Authorization Application for Treatment of Acute Respiratory Distress Syndrome Secondary to COVID -19 with Umbilical…

Saturday, April 18th, 2020

SALT LAKE CITY, April 13, 2020 (GLOBE NEWSWIRE) -- Predictive Biology, a wholly owned subsidiary of Predictive Technology Group (OTC PINK: PRED) (Predictive or The Company), announced that on April 9th it submitted an Emergency Use Authorization (EUA) application with the U.S. Food and Drug Administration (FDA) for the immediate use of mesenchymal stem cells (MSCs) derived from umbilical cord tissue for the treatment of Acute Respiratory Distress Syndrome (ARDS), secondary to SARS-CoV-2, coronavirus disease 2019 (COVID-19).

The pandemic caused by COVID-19 has shown to develop into severe ARDS in 30% of hospitalized patients with a 22%-62% mortality rate (Murthy et al., 2020) for those requiring hospitalization in an intensive care unit. Currently, there is no confirmed treatment that can demonstrate safety or efficacy for the treatment of COVID-19.

Coronavirus can be deadly, in large part because the virus can cause cytokine storms in which the patients own immune system triggers a runaway response causing more damage to the patient, than to the virus it's trying to eliminate, said John Sorrentino, Chairman of Predictive Technology Group. Respiratory distress kills hundreds of thousands of people each year worldwide. There is clinical data from early clinical trials that seem to indicate that the avoidance of the cytokine storm utilizing MSCs may be a critical component for the treatment of COVID-19 infected patients.

A recent review article published in Pain Physician, concluded that, The limited but emerging evidence regarding UC MSC [umbilical cord mesenchymal stem cells] in managing COVID-19 suggests that it might be considered for compassionate use in critically ill patients to reduce morbidity and mortality in the United States.

The proposed IND clinical trial will utilize Predictives proprietary core technology of naturally occurring MSCs derived from umbilical cord tissue (UC-MSCs) to assess the efficacy as an add-on therapy to standard treatment of patients with severe Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19.

Predictives UC MSC product, CoreCyte, [currently regulated by the FDA as a tissue-based product under 21 CFR 1271.3(d)(1) and Section 361 of the Public Health Service Act] has already beenused as an allograft in over50,000 patients. Physicians have reported to Predictive that over 1,100 patients have been treated with CoreCyte via intravenous administration. No serious adverse events have been reported with CoreCyte regardless of the route of administration. If Predictives EUA request is approved, CoreCyte would be available immediately to critically ill patients with ARDS due to COVID-19 infections.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize and personalize precision patient care. The Companys entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests and companion therapeutics in order to support a patient from diagnosis through treatment.

Dedicated to identifying the barriers that impact lifelong health through our genetic library, genomic mapping and individualized diagnostics, Predictives tests and products empower clinicians to provide their patients with the highest level of care. For more information, visit http://www.predtechgroup.com

About Predictive Biotech, Inc.

Predictive Biotech is a leader in regenerative medicine, its products are derived from tissue sources rich in properties that support the bodys natural ability to heal itself. All products are safely, ethically and minimally processed to deliver allografts that preserve the naturally occurring characteristics and factors of the donor tissue. Predictives signature products are uniquely born from the Whartons jelly layer of the umbilical cord and amniotic fluid and tissue.

With over 100,000 units delivered, product safety and consistency has been realized by thousands of practices throughout the United States. A national network of clinics, health systems, researchers and physicians leverage Predictives four proprietary products: AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte.

Forward-Looking Statements:

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks The Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect The Company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect The Company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by The Company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Predictive BiotechInfo@predictivebiotech.com888-407-9761

Investor ContactJeremy FefferLifeSci Advisorsjeremy@lifesciadvisors.com212-915-2568

More:
Predictive Submits Emergency Use Authorization Application for Treatment of Acute Respiratory Distress Syndrome Secondary to COVID -19 with Umbilical...

Read More...

Stem Cell Therapy Market to 2027 – Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography – Salamanca Press

Thursday, April 16th, 2020

NEW YORK, April 15, 2020 /PRNewswire/ -- The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans.This raises the importance of creating public awareness about stem cell research and its clinical potential.

The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user.Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.

The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous.

The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.Based on application type, the stem cell therapy market has been segmented into musculoskeletal, dermatology, cardiology, drug discovery and development, and other applications.

The musculoskeletal segment held the largest share of the stem cell therapy market in 2019, whereas the drug discovery and development segment is expected to report the highest CAGR during 20202027. Based on end user, the market has been segmented into academic and research institutes, and hospitals and specialty clinics. The academic & research institutes held the largest share of the market in 2019, and it is also expected to report the highest CAGR during the forecast period.Several essential secondary sources referred to for preparing this report are the FDA, World Health Organization (WHO), Organisation for Economic Co-operation and Development, National Institutes of Health, Spanish Agency for Medicines (AEMPS), Japanese Society for Regenerative Medicine, and Indian Council of Medical Research, among others.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Excerpt from:
Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography - Salamanca Press

Read More...

Los Angeles Periodontists use blood-derived growth factors as an alternative to treating gum recession – PRNewswire

Thursday, April 16th, 2020

Gum recession puts patients at risk of developing decay, causes tooth sensitivity, and creates an unattractive smile. "Gum recession is most commonly caused by gum disease, which affects nearly 65 million Americans annually. Many patients avoid treatment because of the painful, invasive nature of a gum graft that typically uses gum tissue from the roof of the mouth, increasing post-operative pain and suffering. The RejuvaGum Lift offers patients a gentle yet effective alternative to gum grafting, with less recovery time and enhanced healing," says Dr. Alina Krivitsky.

The Brentwood periodontists utilize cutting-edge technology to offer their patients advanced periodontal care. "Several samples of a patient's blood are spun in a centrifuge to separate the platelets, white blood cells and fibrin. When applied directly to a wound, the proteins in the fibrin encourage faster healing by causing the wound to close more quickly, and increase blood flow to the site. The extra boost of stem cells and growth factors assist in soft tissue regeneration around the exposed roots, and by utilizing the patient's own immune system to heal, the risk of infection is almost none," says Dr. Aalam.

To learn more about the RejuvaGum Lift treatment for gum recession, please visit https://implantperiocenter.com/or contact them at 310-504-1845.

About the CENTER for Advanced Periodontal & Implant Therapy

At the CENTER for Advanced Periodontal & Implant Therapy, Dr. Aalam and Dr. Krivitsky utilize advanced technology coupled with cutting-edge techniques to provide minimally-invasive, comfortable and effective periodontal care. As the only dual-board certified practice in Brentwood, California, they are committed to providing restorative periodontal therapies to rejuvenate the aesthetics, health, and function of the gums and teeth, to help patients achieve a healthier smile.

Contact: Charlene Yashouafar, Marketing DirectorSocial Lighthouse[emailprotected](213) 403-1407

SOURCE The CENTER for Advanced Periodontal & Implant Therapy

WELCOME TO YOUR LOS ANGELES PERIODONTISTS

Link:
Los Angeles Periodontists use blood-derived growth factors as an alternative to treating gum recession - PRNewswire

Read More...

Leading the Movement Towards Direct Cell Conversion: An Interview With Mogrify – Technology Networks

Thursday, April 16th, 2020

Biotech company Mogrify is deploying its proprietary direct cellular conversion technology to develop cell therapies in a variety of disease areas, including auto-immune, musculoskeletal, respiratory diseases and in cancer immunotherapy.The platform utilizes data from next-generation sequencing and cellular networks to identify transcription factors or small molecules required to directly convert a cell, addressing key challenges that are typically associated with the safety and efficacy of cell therapies.Technology Networks recently spoke with Joe Foster, COO, Mogrify, to learn more about the platform, the challenges encountered in developing cell therapies, and to gain Mogrify's insights on the future of this exciting research space.Molly Campbell (MC): What were some of the major highlights for Mogrify in 2019?Joe Foster (JF): In the past year, Mogrify has solidified its reputation as a pioneer in the expanding field of cell therapy. Using a systematic, data-driven approach, our innovative cell conversion platform addresses many of the challenges impeding systematic discovery, process development and the manufacturing processes.At an operational level, Mogrify has seen unprecedented growth in the last year, with emphasis on world-class science. We have established a leadership team with unparalleled track records, including the appointment of Dr Darrin M. Disley OBE, as CEO and Dr Jane Osbourn OBE, as Chair. Looking forward and with plans to boost our team to 70 individuals working across all disciplines, Mogrify has also moved operations to the new Bio-Innovation Centre in Cambridge, giving our team access to state-of-the-art facilities to continue their work in developing novel approaches to cell therapy.Mogrify received MSDs Innovation Award at the 15th Annual Scrip Awards, in acknowledgement of our potential to transform future cell therapies. Dr Jane Osbourn OBE was also the first female to win the Lifetime Achievement Award, recognizing her significant contributions to the biotech industry. Mogrifys significant fundraising success was also marked at the prestigious European Lifestars Awards, which celebrates excellence in the life science industry. Here, Mogrify was recognized as the Seed Stage Finance Raise of the Year.MC: In Mogrify's opinion, what key trends can we expect to see in the cell therapy space in 2020?JF: Many of the current approaches to cell therapy involve first converting cells back into a stem cell-like stateinduced pluripotent stem cellsbefore then converting them into the cell type required.Mogrify plans to lead the movement towards direct cell conversion, or transdifferentiation, where cells can be transformed from one cell type to another, without having to go through an intermediate pluripotent stage. Direct conversion of cells would enhance the speed of cell therapy development, as cells do not need to use traditional developmental pathways to reach a mature state.

Another bottleneck in the delivery of cell therapies is that most approaches rely on autologous transplants, which are carried out using patient-derived cells. Future innovations are moving towards using allogeneic therapies, where the cells used for therapy are derived from a healthy donor. Such advances are paving the way towards the development of universal donor cells, which would turn cell therapies into off-the-shelf treatments, enhancing the scale and accessibility of the treatments.

Finally, cell therapy methods are likely to move from ex vivo approaches (where cells are isolated from the patient, reprogrammed, and delivered back into the patient), to in vivo approaches, where cell therapies are delivered directly to the recipient, for example, through the use of small molecules present in a reprogramming cocktail or direct gene editing. In vivo technologies would, therefore, be able to reprogram cells directly in living humans, expanding the scope of cell therapy in a clinical setting. Overall, future cell therapies will have the capacity to be more effective, safer, and widely accessible.

MC: What are the key challenges that currently exist when developing and testing cell therapies? How does Mogrify hope to overcome such challenges?JF: The biggest challenges in producing cell therapies surround the efficacy, safety profile, and scalability of clinical treatment regimes. To make treatments safer, delivered cells must bypass the host immune system. This can be achieved with autologous therapy, but comes at the cost of scale and efficiency, as the patients cells need to be extracted, cultured, and reprogrammed before treatment can be delivered. Genetic engineering technologies (such as CRISPR/Cas9) that can be employed to remove the antigenic potential of allogeneic cell therapies (e.g. CAR-T) can be used in conjunction with such treatments, but this brings an additional layer of complication.Another difficulty comes from the technical challenges associated with generating, culturing, and expanding the required cells. In theory, any cell type can be derived from pluripotent cells. However, determining precisely how to generate any cell from pluripotent cells is conceptually and practically complex. Each cell type would require a distinct combination of transcription factors (or small molecules) and optimized culture conditions to ensure robust conversion into the desired phenotype. These technical challenges are associated with slow progress and poor efficiency in deriving reliable therapeutic cells.

Mogrify aims to tackle these hurdles with solutions involving big data, computational predictions, and bioinformatics. Mogrifys proprietary algorithm uses next generation sequencing data to predict the combination of transcription factors necessary to reliably convert any cell type into another cell type. Mogrifys technology provides a framework for direct cell conversion, and can also identify the best culture conditions to ensure that the cell populations remain stable and viable. This greatly improves cell therapy efficiency, as mature cells are created without the often arduous and imprecise process of differentiating cells from pluripotency.

Mogrifys technology is also compatible with in vivo cell therapies, as it can identify a combination of small molecules that will drive the necessary transcriptional networks to create the cells of choice. Therefore, Mogrifys technology can also be applied to overcome safety issues associated with allogeneic ex vivo approaches, and has the potential to greatly enhance the scale at which cell therapies can be delivered.MC: Are you able to tell us more about the latest developments in Mogrify's pipeline?JF: Currently, Mogrify is focused on applying the platform to musculoskeletal disorders, cancer immunotherapy, and auto-immune, ocular and respiratory diseases. Specifically, Mogrify is committed to identifying opportunities in regenerative medicine contexts, where direct cell conversion could have strong therapeutic potential.The current lead musculoskeletal program is in the development of chondrocytes for the treatment of cartilage defects and osteoarthritis. Mogrifys platform identified a cocktail of small molecules that successfully drives the conversion of fibroblast cells to chondrocytes, which has been proven to form functional hyaline cartilage in vitro. This can even be performed using an allogeneic approach without the need for gene editing (as the cartilage is immunopriviliged). Thus, it represents an opportunity for an off-the-shelf therapy that could be a relatively inexpensive and accessible treatment. At present, this treatment is in pre-clinical stages, and has a powerful potential for success in regenerative cartilage therapy. Similarly, an in vivo method of transdifferentiating osteoarthritic chondrocytes to healthy cells is being investigated in ongoing studies using a cocktail of small molecules.

Joe Foster, COO, Mogrify was speaking to Molly Campbell, Science Writer, Technology Networks.

Here is the original post:
Leading the Movement Towards Direct Cell Conversion: An Interview With Mogrify - Technology Networks

Read More...

Community resilience is facing Its greatest threat, and colleges are helping | Opinion – pennlive.com

Thursday, April 16th, 2020

Throughout history, the nations colleges and universities have set the foundation for innovation and social change. Weve uncovered the secrets of DNA. Weve unleashed bioengineering. We have harnessed intellectual power to create new technologyoften through the partnerships between land grant colleges and local industries and agriculturebringing the latest science to where it was needed. And we have done it all while demanding intellectual rigor and a sharp focus on the common good for society.

At Boston University, the Center for Regenerative Medicine at BUs Medical Center, alerted by colleagues at the University of Washington in Seattle, coordinated with MITs Broad Institute as well as Harvard to produce a test for the virus with a turn around time of within 24 hours. More than 50 volunteered in this round the clock effort. Testing is now underway. Rutgers University has launched its own virus testing program. Its RUCDR Infinite Biologicsa part of the Universitys Human Genetics Institute of New Jerseyis now capable of testing tens of thousands.

Tiny Bay Mills Community College, a Michigan tribal college of fewer than 500 students, has used 3-D technology to design and now produce 1,000 face masks for first responders every week.

Institutions of higher education, large and small, can and do play a significant role in serving our country and our world at this critical moment in history. But our work starts at home. Whats required is a community approach, as local areas are impacted in distinct ways while this crisis unfolds.

I learned the power of community response to overwhelming challenges at the American University of Nigeria. I served there as president when Boko Haram began to surge near the campus and federal assistance was nowhere to be found. The university brought the community together and kept the terrorist group at bay and fed refugees.

Drawing on that experience, when I arrived at Dickinson three years ago, I immediately began to gather with community members to identify their most pressing issues and to connect them with college resources. What started out as a dozen people has now grown to more than 50 representing nearly every sectornonprofits, school districts, health care, government and business. We are meeting remotely in the age of COVID-19, but the relationships we have built have allowed us to respond quickly in a coordinated manner to the communitys growing needs.

Working with Carlisle Borough, the Chamber of Commerce and Community CARES partnered to convert the Stuart Community Center into a shelter for the homeless. UPMC Carlisle anticipated a potential need for housing and shelter for its exhausted medical workers; Dickinson stepped up and agreed to make space available in our vacated residence halls. Local businesses needed an online presence to offer goods and services, but lacked the know-how; Dickinson students are developing e-commerce websites for those businesses. Our organic farm is supplying much-needed fresh produce for the community.

Colleges areand should beat the epicenter of community responses to COVID. They can and should be the assembly point for community action. Its imperative that colleges start building or strengthening relationships with leaders in their communities now, to help in recovery and before the next crisis or disaster occurs.

When students return to class, they will return to communities that have changed in myriad ways. The old ideas, approaches and leadership simply wont do. Our students and young people are the ones we will need to help us with the necessary reconstruction. Those students will rely on the knowledge and problem-solving skills our institutions of higher learning should be providing.

In these difficult times, the country must demand much of its colleges and universities. Communities must know that we are in the trenches with you, and that we are all of us prepared to do more. When students return to our campuses we should work together to build a program of national service. This is how we will rebuild America and prepare the next generation for more unprecedented challenges.

Margee M. Ensign is president of Dickinson College, in Carlisle. Previously, Ensign served as president of the American University of Nigeria, where she developed aid and relief programs for hundreds of thousands of internally displaced people fleeing Boko Haram.

Continue reading here:
Community resilience is facing Its greatest threat, and colleges are helping | Opinion - pennlive.com

Read More...

ACRO Biomedical’s Proprietary Technology Leads the World with Patents from Taiwan, Japan, USA, and Korea – Yahoo Finance

Thursday, April 16th, 2020

TAIPEI, April 16, 2020 /PRNewswire/ -- ACRO Biomedical Co., Ltd., the first company in the world to utilize "supercritical CO2 extraction technology" on cleansing animal tissues and organs, is gradually showing impressive results on the global patent map. In 2019, ACRO acquired two patents from Japan. One for the decellularized cartilage graft, and another for the decellularized cornea. The great news continues with ACRO acquiring patents from the USA and Korea successively for the decellularized cornea in March 2020.

ACRO has acquired patents from Taiwan, the USA, Japan, and Korea for the preparation of acellular corneas by utilizing supercritical CO2 extraction technology. Patents from India, EU, Hong Kong, andmainland China are also on their way. The wish to benefit patients around the world with damaged cornea is very promising.

The CEO of ACRO Biomedical, DJ Hsieh, said that the traditional way to utilize supercritical CO2 extraction technology is to extract herbal medicine and essential oil. After many years of research and development, ACRO has successfully utilized the technology on cleansing animal tissues and organs including skin, bone, cartilage, cornea, blood vessel, nerve, heart, kidney, liver, pancreas, and brain. Many of the products have received approval from USFDA, Singapore, Vietnam, Philippines, and Taiwan FDA. Furthermore, ACRO has licensed out Collagen Ophthalmic Matrix to Oculus BioMed from Australia, and also signed an exclusive strategic partnership agreement with Marubeni Corporation from Japan, laying the foundation for the global market.

The advantages of ACRO's technology application are its high efficiency, low cost, time-saving, and when compared with other products of the same type that are decellularized with acid-base solutions or organic solvents, it greatly reduces the chance of allergy and immune rejection. It is a great help for the future development of the global regenerative medicine.

SOURCE ACRO Biomedical Co., Ltd.

See the original post:
ACRO Biomedical's Proprietary Technology Leads the World with Patents from Taiwan, Japan, USA, and Korea - Yahoo Finance

Read More...

New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion’s SEP-363856 for the Treatment of Schizophrenia – PharmaLive

Thursday, April 16th, 2020

In this study, once-daily, flexible-dose (50-75 mg) treatment with SEP-363856 demonstrated a statistically significant and clinically meaningful improvement in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo after four weeks of treatment (-17.2 vs. -9.7, respectively; p=0.001). Patients treated with SEP-363856 also showed improvement in the overall severity of illness as assessed by the Clinical Global Impression Scale Severity (CGI-S) (p<0.001). In addition, improvement was observed in all major PANSS (positive, negative and general psychopathology) subscales (p<0.02). SEP-363856 was well tolerated throughout the study and the overall discontinuation rate was comparable for SEP-363856 and placebo.1

These data represent an exciting step forward in schizophrenia research. The steps that led to identifying this new mechanism of action, targeting TAAR1, were very novel and they reflected a courageous and innovative approach by Sunovion to identifying new ways to treat schizophrenia, said John Krystal, M.D., Chair of Psychiatry and Co-Director, Yale Center for Clinical Investigation at Yale School of Medicine and co-author of the NEJM publication. For the last 60 years, antipsychotics that bind to dopamine receptors have been the standard of care, despite their side effect profile. It is my hope that these results for SEP-363856 support a new schizophrenia treatment for people who have been diagnosed with this serious mental health condition. SEP-363856 could have a big impact on people with schizophrenia, their families, and on the public health burden posed by schizophrenia.

SEP-363856 is a novel trace amine-associated receptor 1 (TAAR1) agonist with serotonin 1A (5-HT1A) agonist activity that is being evaluated in patients with schizophrenia. SEP-363856 does not bind to dopamine 2 (D2) or serotonin 2A (5-HT2A) receptors, which are thought to mediate the effects of currently available atypical antipsychotic medicines. SEP-363856 is being studied in the DIAMOND (Developing Innovative Approaches for Mental Disorders) Phase 3 global development program for schizophrenia with additional indications under consideration. The U.S. FDA granted Breakthrough Therapy Designation for SEP-363856 for the treatment of schizophrenia in May 2019.

Publication of these findings in the New England Journal of Medicine demonstrates the potential of SEP-363856 to be the first TAAR1 agonist for the treatment of schizophrenia, said Kenneth Koblan, PhD, Chief Scientific Officer of Sunovion. This innovative approach to the treatment of schizophrenia may provide a completely new option for the 23 million people worldwide who live with this serious mental health condition. Sunovion is committed to developing new treatment options for these patients and continuing to study SEP-363856 to further evaluate its clinical benefit in schizophrenia and other neuropsychiatric conditions.

As noted in the NEJM publication, in the six-month, open-label extension study, SEP-363856 demonstrated continued improvement across efficacy measures, including the PANSS total score, the CGI-S score, and the Brief Negative Symptom Scale (BNSS) total score and appeared to be safe and well-tolerated.

About SEP-363856 SEP-363856 is a TAAR1 agonist with 5-HT1A agonist activity that is under investigation for the treatment of schizophrenia and other psychiatric conditions. Sunovion discovered SEP-363856 in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms. SEP-363856 is being studied in a global Phase 3 development program for schizophrenia (DIAMOND) with additional indications under consideration. The U.S. FDA granted Breakthrough Therapy Designation for SEP-363856 for schizophrenia in May 2019.

About Schizophrenia Schizophrenia is a chronic, serious and often severely disabling brain disorder that affects more than 23 million people worldwide2 and approximately one in 100 adults (about 2.4 million people) in the United States.3 It is characterized by positive symptoms, such as hallucinations, delusions and disorganized thinking as well as negative symptoms, such as lack of emotion, social withdrawal, lack of spontaneity and cognitive impairment that includes problems with memory, attention and the ability to plan, organize and make decisions.2

About Sunovion Pharmaceuticals Inc. (Sunovion) Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovions vision is to lead the way to a healthier world. The companys spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.

Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the companys websites: http://www.sunovion.com, http://www.sunovion.eu and http://www.sunovion.ca. Connect with Sunovion on Twitter, LinkedIn, Facebook and YouTube.

About Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma is among the top-10 listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China, and the European Union. Sumitomo Dainippon Pharma aims to create innovative pharmaceutical products in the Psychiatry & Neurology area, the Oncology area and Regenerative medicine/Cell therapy field, which have been designated as the focus therapeutic areas. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at https://www.ds-pharma.com.

SUNOVION is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. 2020 Sunovion Pharmaceuticals Inc. All rights reserved.

For a copy of this release, visit Sunovions website at http://www.sunovion.com

References

1 Koblan, K., Kent, J., Hopkins, S., Krystal, J., Cheng, H., Goldman, R., Loebel, A., A non-D2 Binding Drug for the Treatment of Schizophrenia. New England Journal of Medicine. April 16, 2020, Vol. 382, Issue 16, p. 1497-1506. Available online: https://www.nejm.org/doi/full/10.1056/NEJMoa1911772. Accessed April 2020. 2 World Health Organization. Mental Disorders. [Internet]. Available from:https://www.who.int/news-room/fact-sheets/detail/mental-disorders. Accessed September 2018. 3 National Institute of Mental Health. Schizophrenia. [Internet]. Available from: https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml. Accessed September 2018.

Follow this link:
New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion's SEP-363856 for the Treatment of Schizophrenia - PharmaLive

Read More...

Global Regenerative Medicine Market : Industry Analysis and Forecast (2019-2026): By Type, Application and Region. – Publicist360

Thursday, April 16th, 2020

Global Regenerative Medicine Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at a XX %CAGR of around 24.3% during a forecast period.

Regenerative medicine is an interdisciplinary field of medicine that is used for developing methods to grow, replace or repair diseased or damaged cells, organs, and tissues. Regenerative medicine contains the generation and use of therapeutic stem cells, tissue engineering and the production of artificial organs.

The report covers all the trends and technologies playing a major role in the growth of the regenerative medicine market over the forecast period. It highlights the drivers, restraints, and opportunities expected to influence market growth during 2019-2026.

Global Regenerative Medicine Market

Regenerative medicines are expected to have a major impact on healthcare to treat specific indications and chronic conditions. Therefore, a high prevalence of cancer, neurodegenerative, orthopedic, and other ageing-associated disorders coupled with increasing worldwide geriatric population is driving the market growth. Additionally, increasing prevalence of inheritable genetic diseases is anticipated to fuel the demand in the field of the biotechnology field. However, high treatment costs, operative inefficiency, stringent government regulations, and lack of awareness will restrict the global market for regenerative medicine.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/35229/

The report on global regenerative medicine market covers segments such as type, application and region. Based on application, oncology segment is estimated to witness the fastest XX% CAGR over the forecast period. Many government organizations, as well as private companies, have made high investments in cancer research and development of regenerative & advanced cell therapies. Global efforts to reduce the cancer burden is expected to support the lucrative growth of the oncology segment.North America is the dominating region in the market for regenerative medicine. The major factors promoting regenerative medicine market growth in this region are growing awareness for the use of these medicines to treat various diseases and rising funding line for developing the product line by the private and government organizations.

However, the APAC is considered to grow at a faster rate during the forecast period because of the increasing focus on research and development on regenerative medicine, various government have taken initiative to treat many diseases with the help of regenerative medicines. The report gives a recent development in the market for regenerative medicine like in 2018, Novartis AG received EU approval for one-time gene therapy Luxturna, which has been developed to restore visualization in people with rare and genetically-associated retinal disease. Additionally, in 2017, Integra LifeSciences launched its product, Integra Dermal Regeneration Template Single Layer Thin for dermal repair faults reconstruction in a one-step procedure.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Regenerative Medicine Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Global Regenerative Medicine Market.Scope of the Global Regenerative Medicine Market

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/35229/

Global Regenerative Medicine Market, By Type

Cell-Based Immunotherapy & Cell Therapy Productso Allogeneic Productso Autologous Products Tissue-Engineered Products Gene Therapy ProductsGlobal Regenerative Medicine Market, By Application

Musculoskeletal Disorders Wound Care Oncology Ocular Disorders Diabetes OtherGlobal Regenerative Medicine Market, By Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey Players operating in the Global Regenerative Medicine Market

Integra LifeSciences Corporation Astellas Pharma Inc. Ocata Therapeutics, Inc. Corline Biomedical AB Cook Biotech, Inc. Bayer BV BlueRock Therapeutics AstraZeneca MedImmune F. Hoffmann-La Roche Ltd Pfizer Inc. Merck & Co., Inc. Sigma-Aldrich Co. LLC Abbott St. Jude Medical, Inc. Vericel Corporation Novartis AG Alcon GlaxoSmithKline plc. Baxter. Synovis Micro Companies Alliance Inc Amgen Inc. Eli Lilly and Company Bristol-Myers Squibb Company iPierian, Inc Nuvasive, Inc. Organogenesis, Inc. NuTech MiMedx Group, Inc. Stability, LLC. Takara Bio Inc. Caladrius Biosciences, Inc. U.S. Stem Cell, Inc. Cesca Therapeutics Osiris Therapeutics, Inc

MAJOR TOC OF THE REPORT

Chapter One: Regenerative Medicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Regenerative Medicine Market Competition, by Players

Chapter Four: Global Regenerative Medicine Market Size by Regions

Chapter Five: North America Regenerative Medicine Revenue by Countries

Chapter Six: Europe Regenerative Medicine Revenue by Countries

Chapter Seven: Asia-Pacific Regenerative Medicine Revenue by Countries

Chapter Eight: South America Regenerative Medicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Regenerative Medicine by Countries

Chapter Ten: Global Regenerative Medicine Market Segment by Type

Chapter Eleven: Global Regenerative Medicine Market Segment by Application

Chapter Twelve: Global Regenerative Medicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Regenerative Medicine Market Report at:https://www.maximizemarketresearch.com/market-report/global-regenerative-medicine-market/35229/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Original post:
Global Regenerative Medicine Market : Industry Analysis and Forecast (2019-2026): By Type, Application and Region. - Publicist360

Read More...

Hot Stock in the Spotlight:: China Regenerative Medicine International Limited (HKSE:8158) – Investor Welcome

Thursday, April 16th, 2020

China Regenerative Medicine International Limited (HKSE:8158) STOCK IN FOCUS:

Overbought and Oversold levels

The stock has RSI reading of 53.08. RSI gives an indication of the impending reversals or reaction in price of a security. RSI moves in the range of 0 and 100. So an RSI of 0 means that the stock price has fallen in all of the 14 trading days. Similarly, an RSI of 100 means that the stock price has risen in all of the 14 trading days. In technical analysis, an RSI of above 70 is considered an overbought area while an RSI of less than 30 is considered as an oversold area. RSI can be used as a leading indicator as it normally tops and bottoms ahead of the market, thereby indicating an imminent correction in the price of a security. It is pertinent to note that the levels of 70 and 30 needs to be adjusted according to the inherent volatility of the security in question.

If you are considering getting into the day trading or stock market, its a legitimate and profitable method for making a living. Every good investor knows that in order to make money on any investment, you must first understand all aspects of it, so lets look at daily change, stock price movement in some particular time frame, volatility update, performance indicators and technical analysis and analyst rating. Picking a stock is very difficult job. There are many factors to consider before choosing a right stock to invest in it. If picking stock was easy, everyone would be rich right? This piece of financial article provides a short snap of China Regenerative Medicine International Limited regarding latest trading session and presents some other indicators that can help you to support yours research about China Regenerative Medicine International Limited.

China Regenerative Medicine International Limited (HKSE:8158) stock Trading Summary:

China Regenerative Medicine International Limited (HKSE:8158) stock changed position at +1.92%% to closing price of HKD$0.265 in recent trading session. The last closing price represents the price at which the last trade occurred. The last price is also the price on which most charts are based; the chart updates with each change of the last price. The stock registered Last trading volume of 426750 shares. Daily volume is the number of shares that are traded during one trading day. High volume is an indication that a stock is actively traded, and low volume is an indication that a stock is less actively traded. Some stocks tend always to have high volume, as they are popular among day traders and investors alike. Other stocks tend always to have low volume, and arent of particular interest to short-term traders. The stock average trading capacity stands with 1.648M shares and relative volume is now at 0.26 .

China Regenerative Medicine International Limited (HKSE:8158) Stock Price Movement in past 50 Days period and 52-Week period

China Regenerative Medicine International Limited stock demonstrated 12-month low at HKD$0-39.62% and unveiled a 12-month high of HKD$1+239.62%. Prices of commodities, securities and stocks fluctuate frequently, recording highest and lowest figures at different points of time in the market. A figure recorded as the highest/lowest price of the security, bond or stock over the period of past 52 weeks is generally referred to as its 52-week high/ low. It is an important parameter for investors (as they compare the current trading price of the stocks and bonds to the highest/lowest prices they have reached in the past 52 weeks) in making investment decisions. It also plays an important role in determination of the predicted future prices of the stock.

China Regenerative Medicine International Limited (HKSE:8158) Stock Past Performance

China Regenerative Medicine International Limited stock revealed 0.06% return for the recent month and disclosed 0.1522% return in 3-month period. The stock grabbed -0.9732% return over five years and -0.47% return in yearly time period. Past performance shows you the funds track record, but do remember that past performance is not an indication of future performance. Read the historical performance of the stock critically and make sure to take into account both long- and short-term performance. Past performance is just one piece of the puzzle when evaluating investments. Understanding how performance fits in with your overall investing strategy and what else should be considered can keep you from developing tunnel vision.

Volatility in Focus:

The stock unfolded Volatility or average true range percent (ATRP 14) at 0.0507%. Volatility is a rate at which the price of a security increases or decreases for a given set of returns. Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks wont necessarily have lower ATR values than higher priced stocks.

Beta factor is now at 0.86. BETA indicates whether a stock is more or less volatile than the market as a whole. A stock that has a beta score higher than 1 means that volatility is high, while less than 1 means that volatility is low.

Read the original post:
Hot Stock in the Spotlight:: China Regenerative Medicine International Limited (HKSE:8158) - Investor Welcome

Read More...

COLUMN Worried about your immune system? Try these 5 natural remedies – Body aches fever chills and nasal congestion common symptoms of the flu can…

Thursday, April 16th, 2020

San Diego Community News Group

Complications arising from these illnesses can become serious, says Dr. Suhyun An (drsuhyunan.com), an expert on regenerative medicine and co-author of Demystifying Stem Cells: A Real-Life Approach To Regenerative Medicine.

An says there are ways to prevent the symptoms from reaching that serious point. To feel better and get back on your feet, she recommends numerous natural cold and flu remedies to alleviate your symptoms:

Vitamin C. Some studies indicate that vitamin C can shorten the lifespan of a cold and boost your immune system. The best way to get it is through your diet; the fresher the food, the better, An says. Oranges, limes, lemons, grapefruits, leafy greens, and bell peppers are all good sources of vitamin C. Be careful with supplements because they can lead to upset stomach and kidney stones.

Honey. Honey has natural antiviral and antimicrobial properties. Drinking honey in tea with lemon can ease sore throat pain, An says. Research suggests that honey is an effective cough suppressant, too. Honey often contains Clostridium bacteria, so never give honey to a child younger than 1-year-old because infants immune systems arent able to fight them off.

Chicken soup. This popular cold and flu remedy helps because hot liquids reduce mucus buildup and keep you hydrated. Chicken soup, in particular, has anti-inflammatory properties, which help reduce a colds unpleasant side effects, An says. Keep some in the freezer or even canned for flu season. Its quick to prepare that way and soothing to eat.

Aromas. When you have congestion from the flu, applying camphor or menthol salve around your nose can help break up mucus, An says. Aromatherapy oils, such as peppermint and eucalyptus, can have a similar effect. Also, vapor rub can reduce cold symptoms, especially in children older than 2 years. It helps open air passages to combat congestion, reduce coughing, and improve sleep. Its a good alternative to over-the-counter cold medicines in young children because of unwanted side effects.

Probiotics. These are friendly bacteria and yeast found in the body, some foods, and supplements. They can help keep your gut and immune system healthy, and they may reduce your chance of getting sick with an upper respiratory infection, An says. For a delicious and nutritious source of helpful bacteria, include probiotic yogurt in your diet.

Colds and the flu are threats to us every year, but they dont have to get us down for long, An says. Natural home remedies can reduce symptoms so you can be more comfortable and get the rest you need to get better faster.

Dr. Suhyun An is the clinic director at Campbell Medical Group in Houston and an expert on regenerative medicine.

See the original post:
COLUMN Worried about your immune system? Try these 5 natural remedies - Body aches fever chills and nasal congestion common symptoms of the flu can...

Read More...

Global Cartilage Repair and Regeneration Market, by Treatment Modalities, Procedure Type and Application to 2022 – Yahoo Finance

Wednesday, April 1st, 2020

Dublin, April 01, 2020 (GLOBE NEWSWIRE) -- The "Global Cartilage Repair and Regeneration Market, by Treatment Modalities (Cell-Based Approach, Non-Cell-Based Approach), by Procedure Type, by Application, Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

Due to changing lifestyle, a number of disorders like obesity and degenerative joint diseases are affecting the masses across the globe. These factors directly or indirectly develop cartilage injuries; and lead to a decline in the productivity of the working population, which ultimately causes some degree of disability. Therefore, increasing epidemiology of such diseases requires effective treatment options, generating significant demand for regenerative medicine used to restore damaged cartilage.

According to this new release, Global Cartilage Repair and Regeneration Market, by Treatment Modalities (Cell-Based Approach, Non-Cell-Based Approach), by Procedure Type, by Application Outlook 2022 , the industry is expanding at a fast pace. As per this report, the Cartilage Repair and Regeneration market are anticipated to witness high double-digit growth during the forecasted period (2016-2022). This report provides a detailed analysis of the current and future market scenario of the global Cartilage Repair and Regeneration market. The report provides insight into the major factors affecting growth, latest innovations, market segmentation, and competitive landscape.

The report segments the market on the basis of the treatment modalities, procedure type, applications, and geography, with the future forecasts on all prominent segments of the industry till 2022.

Based on treatment modality, the cell-based approaches segment accounts for the largest market share in the overall cartilage repair and regeneration market, due to long-term results of these therapies.

In terms of procedure type, microfracture and ACI are the most common procedure observed amongst all the types of the cartilage repair procedure. Furthermore, in terms of application, the hyaline cartilage repair and regeneration market accounts for the largest share in 2016. It is also expected to be the fastest-growing application segment in the cartilage repair and regeneration market. The large share and high growth of this segment can be attributed to the high prevalence of cartilage damage in hyaline cartilage.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America holds the major share in the market. However, the Asia-Pacific region is slated to witness the highest growth in the forecasted period. The growth of the Asia-Pacific market is driven by improving healthcare facilities, raising awareness, increasing prevalence of rheumatoid and osteoarthritis, and increasing government initiatives in this region.

The report finally covers the competitive analysis of the key market players, in terms of their market share and their product offerings. The key vendors dominating the market space are Stryker Corp., Zimmer Biomet Holdings Inc., Smith & Nephew Plc, DePuy Synthes, Inc., etc. The competitive analysis is done at each player level, including their recent developments. To provide a thorough understanding of each player's business model, the player's current and historical financials have been analyzed. Thus, the report provides a comprehensive analysis of cartilage repair & regeneration technology, which will enable investors to design suitable business strategies to target this market.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Cartilage Repair-Overview

4. Market Dynamics4.1 Drivers4.1.1 Growing Incidences of Chondrodystrophies leading to Cartilage Injuries4.1.2 Rising Incidences of Orthopedic Diseases4.1.3 Surge in Sports Injuries4.1.4 Growing Geriatric Popuation4.1.5 Rising Prevalence of Obesity4.1.6 Technological Advancements4.2 Challenges4.2.1 Limited Health Insurance Coverage in Developing Countries4.2.2 High Cost of Knee Cartilage Repair Surgeries4.2.3 Complexity of Cartilage Repair Surgeries4.3 Opportunities4.3.1 Significant US Market Opportunity Due to Unsatisfactory First Line Therapies4.3.2 Emerging Economies to Offer Sustained Growth Opportunities4.3.3 Increased R&D Spending for Advancements in Knee Cartilage Repair4.3.4 Use of Bioactive Growth Factors4.3.5 3D Printing

5. Global Cartilage Repair and Regeneration Market Outlook 2022

6. Cartilage Repair and Regeneration Market, By Treatment Modalities6.1 Cell-Based Approach6.2 Non-Cell-Based Approach

7. Global Cartilage Repair and Regeneration Market, By Procedure Type7.1 Autologous Chondrocyte Transplantation7.2 Cell-Based Cartilage Resurfacing7.3 Microfracture7.4 Osteochondral Allograft7.5 Others

8. Global Cartilage Repair and Regeneration Market, By Application8.1 Hyaline Cartilage Repair and Regeneration8.2 Elastic Cartilage Repair and Regeneration8.3 Fibrous Cartilage Repair and Regeneration

9. Global Cartilage Repair and Regeneration Market, By Geography9.1 North America9.2 Europe9.3 Asia-Pacific

10. Regulatory Landscape

11. Trends & Developments11.1 Cost-Effectiveness Promoting Interest in One-Step Surgery11.2 Bioactive Signals that Enhance Cartilage Repair11.3 Gene Therapy for Cartilage Repair11.4 Mesenchymal Stem Cells

12. Competitive Landscape12.1 Market Share of Key Players12.2 Comparative Analysis of Products

13. Key Players Analysis13.1 Stryker Corporation13.2 B. Braun Melsungen AG13.3 Zimmer Biomet Holdings, Inc.13.4 Smith & Nephew plc13.5 DePuy Synthes, Inc. (A Subsidiary of Johnson & Johnson)13.6 Arthrex, Inc.13.7 Osiris Therapeutics, Inc.13.8 Vericel Corporation13.9 RTI Surgical, Inc.13.10 CONMED Corporation13.11 Anika Therapeutics, Inc.

14. The Future of Cartilage Repair

Story continues

For more information about this report visit https://www.researchandmarkets.com/r/sd7qmv

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read the rest here:
Global Cartilage Repair and Regeneration Market, by Treatment Modalities, Procedure Type and Application to 2022 - Yahoo Finance

Read More...

LETTERS TO THE EDITOR | Opinion – Moscow-Pullman Daily News

Wednesday, April 1st, 2020

I want to add to the praise for the healthcare workers and first responders who are literally our front line in fighting this war we are in against a virus called COVID-19. As a retired medical technologist, I know that drive to do all we can to save the lives of others and not stopping for breaks or meals or even sleep until the work is done. I, thank God, was never in a battle that went on for days and weeks and now months, nor one where my life was at risk everyday when I went to work. Each and every one of you is a hero beyond compare.

In this same war, I am thinking we have not expressed enough praise for another group of frontline workers: those who are working in our grocery stores, hardware stores, drug stores and restaurants to keep us supplied with the essentials we need through this crisis. You are also at higher risk of being exposed than those of us who get to stay home. In positions that have been taken for granted by so many of us in our busy lives, we can now see you for the hugely important role you have always played in keeping society moving smoothly. Thank you.

Support for the most vulnerable

I am writing you to urge the support of legislation that addresses the needs of the most vulnerable:

1) $60 billion for the charitable sector and the construction of a mechanism for a rapid infusion of cash to those organizations serving immediate needs in communities while facing lost and declining revenue due to the pandemic.

2) Create a universal charitable deduction and allow post-March 1, 2020, donations to be claimed on 2019 taxes and future tax returns.

3) Clarify that charitable nonprofits of all sizes are able to participate in the emergency small business loan program by using the tax-law definition of charitable organizations (Sec. 501(c)(3) public charities).

4) Remove the cap on the number of employees and the language excluding nonprofits from receiving Medicaid reimbursements.

5) Increase funding for the Emergency Food and Shelter Program from the existing FY 2020 $125 million to $250 million to help people experiencing dire poverty.

6) Temporarily increase the maximum SNAP benefit.

7) Increase funding to prevent further homelessness. Provide an additional $15 billion for McKinney-Vento Emergency Solutions Grants and $5 billion for short-term rental assistance, like the Disaster Housing Assistance Program.

Thank you for acting in the welfare of the most vulnerable. Our society can only be as strong as our weakest links.

Making a false supposition

In Kenneth Gordons March 26 letter, (Facts vs. Hysteria), he maintained a false supposition: that COVID-19 is a form of flu. COVID-19 is not a form of flu, it is more akin to another coronavirus, the very deadly SARS (Severe Acute Respiratory Syndrome).

COVID-19 is a novel coronavirus, which is an infectious respiratory illness as is influenza; but this is a brand new virus. That means unlike the flu, which has a vaccine and several pharmaceutical therapies (including oseltamivir phosphate or Tamiflu), there are no vaccines or medicines available to treat the illness yet. Clinical trials for effective treatments and vaccines takes time. Another major concern is because COVID-19 is so new, scientists and medical researchers do not yet know if there are any long-term medical implications with this new virus or how frequently it mutates.

What the medical community does know is this new virus kills at a higher rate than influenza. Currently, the Journal of the American Medical Association estimates the virus is killing at a rate of 2.7 percent compared to a death rate of 1 percent for influenza, although the death rate in Italy is 7.2 percent. The World Health Organization is currently saying little slows this bug down, except for being well informed: Social distancing, sneezing/coughing into elbows and people being vigilant in not touching their face plus hand washing, and paying attention to any symptoms.

So, rather than worry about going back to work, instead consider your fellow humans while you may only show few or no symptoms, that germ you pass on may kill another person. Is going back to work fast really worth that risk?

Knowing it is all for the best

I am always thinking of ways to keep in touch with old friends and family from afar, so I am using this letter to the editor to more widely let known I am fine and am not affected yet by COVID 19.

Because of my interest in history, I have been thinking about other pandemics such as typhoid fever and polio and am encouraged by the fact that these diseases are no longer a threat. My grandfather, I believe, contracted typhoid fever from drinking contaminated water in the Wisconsin Dells.

And I remember how relieved I was during the polio epidemic to finally be able to take polio vaccine. We have come a long way with penicillin other miracle drugs, and I want to put in a plug for the advances in regenerative medicine now on the horizon, specifically stem cell therapy that I underwent this past year. One of the advantages of that is that it only took a half day and I could avoid a prolonged hospital stay. With the fear of contamination and spread of viruses, that was significant for me. I miss seeing you all but know it is for the best.

Drinking poison wastheir own mistake

Propylene glycol is used in many processed foods. Ethylene glycol is the main ingredient in antifreeze. They have similar names, but you wouldnt want to drink antifreeze. That would be stupid. Im sure that Charlie Powell (Tooth & Nail, Daily News), who I believe has a personal acquaintance with veterinarians at WSU, has seen what happens to dogs that dip their tongues in antifreeze.

Recently, we learned of an unfortunate couple of people who tried to self-medicate by drinking poison. The poison has a name similar to a common drug that could be an effective treatment for COVID-19. That is very sad, but obviously it was less than wise.

The drug in question has been safely used for decades to treat a variety of ailments, and doctors around the world have seen promising results against the new coronavirus. Mr. Powell, in his March 28 column, notes that there is an elected official who has mentioned this hopeful development, and then clearly suggests that the elected official is responsible for the actions of those unfortunately mistaken people. Negative, Mr. Powell!

People need to be aware of what they are doing, and if they purposely drink poison, its their own mistake. Theirs alone. Sad, but true.

See the original post here:
LETTERS TO THE EDITOR | Opinion - Moscow-Pullman Daily News

Read More...

Avectas partners with Vycellix to speed cell therapy production – BioPharma-Reporter.com

Wednesday, April 1st, 2020

Avectas will provide access to its Solupure platform, which Vycellix will use to deliver its product candidate, VY-M, to T cells and NK cells.

According to Vycellixs president, Douglas Calder, the use of Solupure will allow for the accelerated expansion time of T cells and NK cells by decreasing the non-dividing lag times the overall aim being to reduce the vein-to-vein delivery time to patients.

In addition, the companies hope to reduce the cost of manufacture and to develop proprietary approaches for cell-based immunotherapeutic products.

Both companies are partners within NextGenNK, a center based on the development of NK cell-based cancer immunotherapies in Stockholm, Sweden.

The collaborative studies that will occur between the two partners will be divided between the Karolinska Institutet and Avectas Dublin, Ireland facility.

Vycellix willl use this platform to aid in the development of its pipeline of therapies, which includes VY-101 a retargeted optimized NK cell therapy. The company hopes to be able to submit an investigational new drug filing in 2021 for the treatment candidate.

Avectas recently signed an agreement to also utilize the platform alongside the Centre for Commercialization of Regenerative Medicine to speed up the cell engineering process.

The companys Solupure platform uses membrane disruption to deliver nucleic acids and proteins to cells rather than viral cell engineering.

Read more:
Avectas partners with Vycellix to speed cell therapy production - BioPharma-Reporter.com

Read More...

Allergan Earns ENERGY STAR Partner of the Year – Sustained Excellence Award for the Seventh Consecutive Year – Yahoo Finance

Wednesday, April 1st, 2020

DUBLIN, March 31, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it has received the ENERGY STAR Partner of the Year Sustained Excellence Award for 2020, marking the seventh consecutive year it has earned ENERGY STAR'shighest honor. The U.S. Environmental Protection Agency award recognizes Allergan for its continued leadership in energy management and efficiency.

"Allergan is proud of its longstanding commitment to increasing our energy efficiency and reducing our impact on the environment. Four years ago, we set an aggressive goal to reduce our total energy usage by 20 percent between 2015 and 2020 and today we are well on our way to achieving that goal. We congratulate our global colleagues for their tremendous efforts to support environmental responsibility, which continue to be recognized year after year," saidWayne Swanton, Executive Vice President, Global Operations atAllergan.

Prior to earning the ENERGY STAR Sustained Excellence distinction for the last seven years, Allergan was recognized as an ENERGY STAR Partner of the Year for two consecutive years. Additionally, Allergan's manufacturing facility in Waco, Texas was recently named an ENERGY STAR Certified Manufacturing Plant for superior energy performance, a distinction earned only by plants in the top 25 percent of energy performance in the United States. Allergan also achieved ENERGY STAR certification for a building located at its Irvine, California campus.Allerganhas been an ENERGY STARpartner since 1996.

For a complete list of 2020 winners and more information about ENERGY STAR's awards program, visit energystar.gov/awardwinners.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website atwww.Allergan.com.

About ENERGY STAR

ENERGY STARis the government-backed symbol for energy efficiency, providing simple, credible, and unbiased information that consumers and businesses rely on to make well-informed decisions. Thousands of industrial, commercial, utility, state, and local organizationsincluding more than 40 percent of the Fortune 500 companiesrely on their partnership with EPA to deliver cost-saving energy efficiency solutions. Since 1992, ENERGY STAR and its thousands of partners helped American families and businesses save more than 4 trillion kilowatt-hours of electricity and achieve over 3.5 billion metric tons of greenhouse gas reductions. In 2018 alone, ENERGY STAR and its partners helped Americans avoid nearly $35 billion in energy costs. More background information about ENERGY STAR can be found at: energystar.gov/about and energystar.gov/numbers.

Story continues

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences;difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:

Allergan: Investors:Manisha Narasimhan, PhD(862) 261-7488

Media:Lisa Brown(862) 261-7320

View original content to download multimedia:http://www.prnewswire.com/news-releases/allergan-earns-energy-star-partner-of-the-year--sustained-excellence-award-for-the-seventh-consecutive-year-301032547.html

SOURCE Allergan plc

Continue reading here:
Allergan Earns ENERGY STAR Partner of the Year - Sustained Excellence Award for the Seventh Consecutive Year - Yahoo Finance

Read More...

Here are the departments accepting S/NC in spring 2020 – The Stanford Daily

Wednesday, April 1st, 2020

On Thursday, the Faculty Senate voted 36-15 to mandate that all spring quarter courses be graded on a satisfactory/no-credit (S/NC) basis. Courses in the Stanford Graduate School of Business, Stanford Law School and Stanford School of Medicines M.D. program were exempt from this decision, but those schools may opt in.

The Senate also approved a measure that strongly urges departments and programs to exclude units of credit earned for a CR or S grade during spring quarter 2019-20 from program unit maximums and/or alter program requirements as appropriate.

The Daily has reached out to all of Stanfords departments, schools and programs that offer undergraduate and/or graduate degrees to compile a list of those accepting courses taken on a S/NC basis this spring for degree requirements. Ways of Thinking/Ways of Doing, Thinking Matters and Program in Writing and Rhetoric courses taken S/NC in the spring will also count toward undergraduate graduation requirements.

No departments, schools or programs have yet said that they will not be accepting courses taken S/NC this spring. The following list will be updated as The Daily receives additional responses.

Graduate School of EducationEducation (Minor)

School of Earth, Energy & Environmental Sciences (All degrees)

School of EngineeringAeronautics and Astronautics (Major, Minor)Architectural Design (Major)Atmosphere and Energy (Major)Bioengineering (All degrees)Biomechanical Engineering (Major)Biomedical Computation (Major)Chemical Engineering (Major, Minor)Civil Engineering (Major, Minor)Computer Science (Major, Minor, M.S.)Electrical Engineering (Major, Minor)Engineering Physics (Major)Environmental Systems Engineering (Major, Minor)Management Science and Engineering (Major, Minor)Materials Science and Engineering (Major, Minor)Mechanical Engineering (All degrees)Product Design (Major)

School of Humanities & SciencesAmerican Studies (Major, Minor)Applied Physics (All degrees)Archaeology (Major, Minor)Biology (Major, Minor)Center for Comparative Studies in Race & Ethnicity (Major, Minor)Chemistry (Major, Minor)Classics (Major, Minor)Communication (All degrees)Creative Writing (Minor)Data Science (Minor)Division of Literatures, Cultures, and Languages (All degrees)Economics (Major, Minor)English (Major, Minor)Human Biology (Major, Minor)Human Rights (Minor)International Relations (Major, Minor)Linguistics (Major, Minor)Mathematical and Computational Science (Major, Minor)Mathematics (Major, Minor)Music (Major, Minor)Philosophy (Major, Minor)Physics (Major, Minor)Political Science (Major, Minor)Psychology (Major, Minor)Public Policy (Major, Minor)Religious Studies (Major, Minor)Sociology (Major, Minor)Statistics (Minor)Symbolic Systems (Major, Minor)Urban Studies (Major, Minor)

School of MedicineBiochemistry (All degrees)Bioengineering (All degrees)Biomedical Informatics (All degrees)Biophysics (All degrees)Cancer Biology (All degrees)Chemical and Systems Biology (All degrees)Epidemiology & Clinical Research (M.S., Ph.D.)Genetics (All degrees)Health Policy (M.S., Ph.D.)Immunology (All degrees)Microbiology and Immunology (All degrees)Neurosciences (All degrees)Stem Cell Biology and Regenerative Medicine (All degrees)

Contact Camryn Pak at cpak23 at stanford.edu.

See the original post here:
Here are the departments accepting S/NC in spring 2020 - The Stanford Daily

Read More...

Coronavirus: BU Wednesday Roundup | BU Today – BU Today

Wednesday, April 1st, 2020

If you have a question or comment related to BU and its response to the COVID-19 crisis, on the subject of the move-out, remote learning, retrieving personal belongings, or anything else, please visit Boston Universitys special COVID-19 website. Questions are being answered there by specific departments in a timely fashion. Thank you. Doug Most, executive editor, BU Today

Even the dogs wont come downstairs.

Number killed in the 9/11 attacks:

2,977

BU-based Boston Playwrights Theatre (BPT) will present a very different Boston Theater Marathon when the annual event begins today, Wednesday, April 1, and it might be just the distraction that all us shut-ins need.

More than 200 Boston-area theater artists are working on Boston Theater Marathon XXII: Special Zoom Edition, which features 10-minute plays written by New England playwrights and presented by New England theater companies. There will be one broadcast every day at noon for more than a month on Zoom, the videoconferencing tool that just about everyone is using to stay in touch these days. Find a complete schedule, with Zoom links, here.

The Elliot Norton Awardwinning marathon, a yearly community-based charity event benefiting the Theatre Community Benevolent Fund, was scheduled for April 19, but was canceled as the coronavirus pandemic escalated earlier this month. Audiences who dial in to the event will be encouraged to donate to participating theater companies and/or to the Theatre Community Benevolent Fund.

We wont let this necessary distancing stop these gifted playwrights and these wonderful companies from coming together to celebrate new work, says BPT and Marathon artistic director Kate Snodgrass (GRS90), a College of Arts & Sciences professor of the practice of playwriting. Theater will continuewhether its on the stage or in our hearts (or rather, in this case, on Zoom). Whether its for 10 minutes or for 10 hours, art lives.

This years Theater Marathon was intended to be a homecoming of sortsthe first time the event had been held at Boston Playwrights Theatre since 2004. (It was at the Huntington Theatre Companys Virginia Wimberly Theatre at the Boston Center for the Arts from 2005 to 2019.) Instead of honoring our past, times dictate that we try something new, says K. Alexa Mavromatis (GRS11), BPT marketing director.

Todays first installment is Three Ladybugs, by Vicki Meagher, sponsored by Boston Playwrights Theatreand featuring an all-BU cast. Its directed by Darren Evans (CAS95), stars Melinda Lopez (GRS00), a CAS adjunct assistant professor of playwriting, as Atheist Ladybug, and veteran Boston stage actors Paula Plum (CFA75) as Agnostic Ladybug and Karen McDonald (CFA72) as Believer Ladybug. Snodgrass and Evans have voice-over parts (Woman and Man) and Mavromatis will read stage directions. Playwrights represented this year include Mavromatis and Ronn Noone (GRS01), as well as local stalwarts like Patrick Gabridge and John Kuntz (GRS05).

The Theater Marathon is traditionally presented as a 10-hour, all-day affair featuring 10-minute plays by 50 New England playwrights and produced by 50 New England theater companies. Instead, this year it will be a daily Zoom-based lunch break through May 17. Readings will begin each day at noon and last approximately 15 minutes. Audiences will need to download the free Zoom app to participate, and it is recommended that they call in a few minutes before curtain time. Nearly every playwright and theater company tapped to participate in the onstage version will be part of the Zoom event.

And yes, the Zoom events will be set up so only the performers are seen and heard.

On Thursday, April 2, all BU alumni, students, faculty, and staff across the globe are asked to wear BU gear for the day and post proudly across social channels using #TerriersTogetheralong with messages of positivity and connection for the BU community. The #TerriersTogether web page asks students and alums to:

The page also offers downloadable Zoom backgrounds so at your next meeting you can make it look like youre at the BU Beach or the GSU.

A couple of BU Today stories we want to be sure you didnt miss: 50 Boston collaborators gathered at the Center for Regenerative Medicine (CReM) on Boston Universitys Medical Campus in March to develop their own FDA-approved coronavirus test. A Questrom supply-chain expert says stock up, yes, but dont panic about food supplies. Also: Former Patriots tight end Rob Gronkowski and model Camille Kostek have donated 10,000 medical-grade KN95 masks to both Boston Medical Center and St. Josephs University Medical Center in New Jersey, in an effort to assist with the high demand for personal protective equipment (PPE) during the pandemic. And finally, if you have followed the conventional wisdom as it evolves toward everybody wear a mask when you go outside, heres how to make your own.

The Massachusetts governor announced Tuesday that he is extending the order closing nonessential businesses and that the state Department of Public Health will keep its stay-at-home advisory in place, both until May 4, matching planned school closures. Gatherings larger than 10 people are also banned. The White House on Sunday extended guidelines for Americans to maintain social distancing through April 30.

An updated list of essential businesses is being distributed. Among the changes: hotels, motels, and short-term rentals like AirBnBs can no longer be booked for leisure purposes. They may be used only for efforts related to fighting COVID-19, like frontline health workers, or for Massachusetts residents who have been otherwise displaced from their residences. People should really be using common sense and not going on vacation right now, Baker said.

The FBI has received multiple reports of conferences being disrupted by pornographic and/or hate images and threatening language, the Boston Globe reports. Apparently, now that were all using Zoom to study and stay connected in an age of social distancing, it has become fertile ground for trolls and hate-mongers. The feds recommend that you use passwords and other Zoom features to prevent disrupters from getting into your work meetings and virtual cocktail parties.

The White House released the epidemiological models of the spread of coronavirus in the United States that painted such a grim picture that President Trump gave up his plan to reopen the country on Easter. Trump warned Americans of a very, very painful two weeks ahead. The models showed the virus is likely to kill 100,000 to as many as 240,000Americans this year. Trump now says social distancing and business closures will continue through April.

A nationwide trial is underway to see if the drug hydroxychloroquine can prevent disease in people exposed to the novel coronavirus. A second trial will test to see if the drug can prevent severe disease in people who are already showing COVID-19 symptoms. Both are run by a University of Minnesota infectious disease specialist.

United States, 174,467; Massachusetts, 6,620.

FindBU Todays latest coverage of the pandemichere. The Universitys hotline for faculty, staff, students, and visiting scholars to call for referral of their virus-related medical concerns is 617-358-4990.

Read the original post:
Coronavirus: BU Wednesday Roundup | BU Today - BU Today

Read More...

Page 25«..1020..24252627..3040..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick